Optimal switching strategies in multi-drug therapies for chronic diseases
Authors:
Juan Magalang,
Javier Aguilar,
Jose Perico Esguerra,
Édgar Roldán,
Daniel Sanchez-Taltavull
Abstract:
Antimicrobial resistance is a threat to public health with millions of deaths linked to drug resistant infections every year. To mitigate resistance, common strategies that are used are combination therapies and therapy switching. However, the stochastic nature of pathogenic mutation makes the optimization of these strategies challenging. Here, we propose a two-scale stochastic model that consider…
▽ More
Antimicrobial resistance is a threat to public health with millions of deaths linked to drug resistant infections every year. To mitigate resistance, common strategies that are used are combination therapies and therapy switching. However, the stochastic nature of pathogenic mutation makes the optimization of these strategies challenging. Here, we propose a two-scale stochastic model that considers the effective evolution of therapies in a multidimensional efficacy space, where each dimension represents the efficacy of a specific drug in the therapy. The diffusion of therapies within this space is subject to stochastic resets, representing therapy switches. The boundaries of the space, inferred from coarser pathogen-host dynamics, can be either reflecting or absorbing. Reflecting boundaries impede full recovery of the host, while absorbing boundaries represent the development of antimicrobial resistance, leading to therapy failure. We derive analytical expressions for the average absorption times, accounting for both continuous and discrete genomic changes using the frameworks of Langevin and Master equations, respectively. These expressions allow us to evaluate the relevance of times between drug-switches and the number of simultaneous drugs in relation to typical timescales for drug resistance development. We also explore realistic scenarios where therapy constraints are imposed to the number of administered therapies and/or their costs, finding non-trivial optimal drug-switching protocols that maximize the time before antimicrobial resistance develops while reducing therapy costs.
△ Less
Submitted 4 December, 2024; v1 submitted 25 November, 2024;
originally announced November 2024.
Analytic and Monte Carlo Approximations to the Distribution of the First Passage Time of the Drifted Diffusion with Stochastic Resetting and Mixed Boundary Conditions
Authors:
Juan Magalang,
Riccardo Turin,
Javier Aguilar,
Laetitia Colombani,
Daniel Sanchez-Taltavull,
Riccardo Gatto
Abstract:
This article introduces two techniques for computing the distribution of the absorption or first passage time of the drifted Wiener diffusion subject to Poisson resetting times, to an upper hard wall barrier and to a lower absorbing barrier. The first method, which we call ``Padé-partial fraction'' approximation, starts with the Padé approximation to the Laplace transform of the first passage time…
▽ More
This article introduces two techniques for computing the distribution of the absorption or first passage time of the drifted Wiener diffusion subject to Poisson resetting times, to an upper hard wall barrier and to a lower absorbing barrier. The first method, which we call ``Padé-partial fraction'' approximation, starts with the Padé approximation to the Laplace transform of the first passage time distribution, which is then exactly inverted by means of the partial fraction decomposition. The second method, which we call "multiresolution algorithm", is a Monte Carlo technique that exploits the properties of the Wiener process in order to generate Brownian bridges at increasing levels of resolution. Our numerical study reveals that the multiresolution algorithm has higher efficiency than standard Monte Carlo, whereas the faster Padé-partial fraction method is accurate in various circumstances and provides an analytical formula. Also, a closed-form exact expression for the expected first passage time is derived.
△ Less
Submitted 24 August, 2024; v1 submitted 7 November, 2023;
originally announced November 2023.
